SEP 24, 2021 7:40 AM PDT

WHO Recommends Antibody Treatment for High Risk COVID-19 Patients

WRITTEN BY: Annie Lennon

The World Health Organization (WHO) has recommended a combination of two antibody treatments for patients at risk of adverse outcomes from COVID-19 infection. The corresponding guidelines with details of the underlying research were published in BMJ Medicine

With the fast pace of COVID-19 research, clinicians must have access to vetted and peer-reviewed research as it becomes available so they can best manage patients. The WHO's recommendations are a part of a living guideline to provide up-to-date and trustworthy guidance to doctors. The current guidelines supersede previous recommendations made on 6 July 2021. 

The drugs recommended by the WHO are called casirivimab and imdevimab. Both are monoclonal antibodies that, when used together, bind to the SARS-CoV-2 spike protein and prevent it from infecting cells where it can then multiply. 

From three trials that are yet to be peer-reviewed, the drugs appear to reduce the risk of hospitalization and duration of symptoms in those at the highest risk of severe disease. This includes people who are unvaccinated, older, or have weaker immune systems. 

Data from the RECOVERY trials also show that the drug combo may be able to reduce the chance of death among patients who are critically and severely ill with COVID-19, as well as their need for mechanical ventilation. These benefits, however, only appear significant for those who are seronegative- those who have not yet developed an antibody response to the virus. 

While the WHO recommends the combo treatment for now, they note that it is subject to change as new variants emerge. They also note that the treatment may be of limited use in low and middle-income countries due to cost and resource implications of rapid serological tests to identify patients, and staff and equipment to deliver and monitor intravenous drug delivery and allergic reactions. 

 

Sources: BMJ MedicineEurekAlert

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 29, 2021
Drug Discovery & Development
A low-cost drug for the treatment of hepatitis.
JUL 29, 2021
A low-cost drug for the treatment of hepatitis.
      The viral disease, Hepatitis C, is known as a silent killer. Hepatitis C is easily spread thro ...
JUL 31, 2021
Cannabis Sciences
Can CBD Treat Psoriasis?
JUL 31, 2021
Can CBD Treat Psoriasis?
With cannabidiol (CBD) becoming increasingly available, many are wondering about its utility in treating various conditi ...
AUG 05, 2021
Cannabis Sciences
Brain's Version of THC Reduces Seizures, Increases Side Effects
AUG 05, 2021
Brain's Version of THC Reduces Seizures, Increases Side Effects
An endocannabinoid similar to tetrahydrocannabinol (THC) that naturally occurs in the brain reduces seizure activity. Ho ...
AUG 20, 2021
Drug Discovery & Development
One Vaccine to Rule Them All: Researchers One Step Closer to Universal Vaccine
AUG 20, 2021
One Vaccine to Rule Them All: Researchers One Step Closer to Universal Vaccine
Researchers have identified two antibodies that can protect animals from diseases caused by alphaviruses, which are RNA ...
SEP 23, 2021
Drug Discovery & Development
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
SEP 23, 2021
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
Last week, the United States Food and Drug Administration (FDA) granted approval for the first oral therapy to ...
SEP 27, 2021
Microbiology
Rift Valley Fever's Infectious Secret is Revealed
SEP 27, 2021
Rift Valley Fever's Infectious Secret is Revealed
Rift Valley fever virus is carried by mosquitoes, and when it's passed to livestock including cattle, goats, and sheep, ...
Loading Comments...